Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Prostate Cancer

  Free Subscription

Articles published in Clin Cancer Res

Retrieve available abstracts of 60 articles:
HTML format

Single Articles

    November 2022
  1. LIM EA, Bendell JC, Falchook GS, Bauer TM, et al
    Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors.
    Clin Cancer Res. 2022;28:4871-4884.
    PubMed     Abstract available

  2. QUINN Z, Leiby B, Sonpavde G, Choudhury AD, et al
    Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate Resistant Prostate Cancer.
    Clin Cancer Res. 2022 Nov 2. pii: 710187. doi: 10.1158/1078-0432.CCR-22-2526.
    PubMed     Abstract available

  3. MATSUBARA N, de Bono J, Olmos D, Procopio G, et al
    Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2 or ATM Alterations Identified by Testing Circulating Tumor DNA.
    Clin Cancer Res. 2022 Nov 1. pii: 710156. doi: 10.1158/1078-0432.CCR-21-3577.
    PubMed     Abstract available

    October 2022
  4. FENG E, Rydzewski NR, Zhang M, Lundberg A, et al
    Intrinsic Molecular Subtypes of Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2022 Oct 19. pii: 709863. doi: 10.1158/1078-0432.CCR-22-2567.
    PubMed     Abstract available

  5. VAISHAMPAYAN UN, Thakur A, Chen W, Deol A, et al
    Phase II trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody Armed Activated T Cells in Metastatic Castrate Resistant Prostate Cancer.
    Clin Cancer Res. 2022 Oct 18. pii: 709809. doi: 10.1158/1078-0432.CCR-22-1601.
    PubMed     Abstract available

  6. FENDLER WP, Pabst KM, Kessler L, Fragoso Costa P, et al
    Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities.
    Clin Cancer Res. 2022;28:4346-4353.
    PubMed     Abstract available

    September 2022
  7. PLYM A, Zhang Y, Stopsack KH, Jee YH, et al
    Family history of prostate and breast cancer integrated with a polygenic risk score identifies men at highest risk of dying from prostate cancer before age 75 years.
    Clin Cancer Res. 2022 Sep 14. pii: 709205. doi: 10.1158/1078-0432.CCR-22-1723.
    PubMed     Abstract available

  8. SWAMI U, Graf RP, Nussenzveig RH, Fisher V, et al
    SPOP mutations as a Predictive Biomarker for Androgen Receptor-Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer.
    Clin Cancer Res. 2022 Sep 11. pii: 709162. doi: 10.1158/1078-0432.CCR-22-2228.
    PubMed     Abstract available

    August 2022
  9. CHI KN, Barnicle A, Sibilla C, Lai Z, et al
    Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound.
    Clin Cancer Res. 2022 Aug 31:OF1-OF11. doi: 10.1158/1078-0432.CCR-22-0931.
    PubMed     Abstract available

    July 2022
  10. NGUYEN DT, Yang W, Renganathan A, Weimholt C, et al
    Acetylated HOXB13 Regulated Super Enhancer Genes Define Therapeutic Vulnerabilities of Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2022 Jul 18. pii: 707054. doi: 10.1158/1078-0432.CCR-21-3603.
    PubMed     Abstract available

  11. AGGARWAL R, Starodub AN, Koh BD, Xing G, et al
    Phase 1b Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2022 Jul 11. pii: 706956. doi: 10.1158/1078-0432.CCR-22-0175.
    PubMed     Abstract available

  12. FISHER NC, Byrne RM, Leslie H, Wood C, et al
    Biological misinterpretation of transcriptional signatures in tumour samples can unknowingly undermine mechanistic understanding and faithful alignment with preclinical data.
    Clin Cancer Res. 2022 Jul 6. pii: 706888. doi: 10.1158/1078-0432.CCR-22-1102.
    PubMed     Abstract available

  13. WANG T, Song W, Chen Y, Chen R, et al
    Correction: Flightless I Homolog Represses Prostate Cancer Progression through Targeting Androgen Receptor Signaling.
    Clin Cancer Res. 2022;28:2970.

    June 2022
  14. SOWALSKY AG, Figueiredo I, Lis RT, Coleman I, et al
    Assessment of Androgen Receptor splice variant-7 as a biomarker of clinical response in castration-sensitive prostate cancer.
    Clin Cancer Res. 2022 Jun 13. pii: 704873. doi: 10.1158/1078-0432.CCR-22-0851.
    PubMed     Abstract available

  15. CHAKRABORTY G, Nandakumar S, Hirani R, Nguyen B, et al
    The impact of PIK3R1 mutations and insulin-PI3K-glycolytic pathway regulation in prostate cancer.
    Clin Cancer Res. 2022 Jun 7. pii: 699404. doi: 10.1158/1078-0432.CCR-21-4272.
    PubMed     Abstract available

  16. CHOUDHURY AD, Higano CS, de Bono JS, Cook N, et al
    A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kbeta/delta, in Patients with Advanced Solid Tumors.
    Clin Cancer Res. 2022;28:2257-2269.
    PubMed     Abstract available

    May 2022
  17. ZHAO N, Chopra S, Trepka K, Wang YH, et al
    CUB domain containing protein 1 (CDCP1) is a target for radioligand therapy in castration resistant prostate cancer including PSMA null disease.
    Clin Cancer Res. 2022 May 23. pii: 699115. doi: 10.1158/1078-0432.CCR-21-3858.
    PubMed     Abstract available

  18. COLEMAN IM, DeSarkar N, Morrissey C, Xin L, et al
    Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration Resistant Prostate Cancer.
    Clin Cancer Res. 2022 May 12. pii: 698880. doi: 10.1158/1078-0432.CCR-21-4289.
    PubMed     Abstract available

  19. SHEEHAN B, Neeb A, Buroni L, Paschalis A, et al
    Prostate Specific Membrane Antigen Expression and Response to DNA Damaging Agents in Prostate Cancer.
    Clin Cancer Res. 2022 May 12. pii: 698876. doi: 10.1158/1078-0432.CCR-21-4531.
    PubMed     Abstract available

    April 2022
  20. MARKOWSKI MC, Tutrone R, Pieczonka C, Barnette KG, et al
    A Phase 1b/2 Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men With Metastatic Castration-Resistant Prostate Cancer with Progression on an Androgen Receptor Targeting Agent.
    Clin Cancer Res. 2022 Apr 13. pii: 694403. doi: 10.1158/1078-0432.CCR-22-0162.
    PubMed     Abstract available

  21. SWEENEY CJ, Percent IJ, Babu S, Cultrera JL, et al
    Phase 1b/2 Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2022 Apr 1. pii: 694115. doi: 10.1158/1078-0432.CCR-21-2326.
    PubMed     Abstract available

  22. WESTPHALEN CB, Fine AD, Andre F, Ganesan S, et al
    Pan-cancer Analysis of Homologous Recombination Repair-associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score.
    Clin Cancer Res. 2022;28:1412-1421.
    PubMed     Abstract available

    February 2022
  23. DE KOUCHKOVSKY I, Rao A, Carneiro BA, Zhang L, et al
    A phase Ib/II study of the CDK 4/6 inhibitor ribociclib in combination with docetaxel plus prednisone in metastatic castration-resistant prostate cancer.
    Clin Cancer Res. 2022 Feb 17. pii: 681559. doi: 10.1158/1078-0432.CCR-21-4302.
    PubMed     Abstract available

  24. SERRITELLA AV, Shevrin D, Heath EI, Wade JL, et al
    Phase I/II trial of enzalutamide and mifepristone, a glucocorticoid receptor antagonist, for metastatic castration-resistant prostate cancer.
    Clin Cancer Res. 2022 Feb 2. pii: 1078-0432.CCR-21-4049.
    PubMed     Abstract available

    January 2022
  25. HUSSAIN M, Corcoran C, Sibilla C, Fizazi K, et al
    Tumor Genomic Testing for >4000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib).
    Clin Cancer Res. 2022 Jan 28. pii: 1078-0432.CCR-21-3940.
    PubMed     Abstract available

  26. DYLGJERI E, Kothari V, Shafi AA, Semenova G, et al
    A Novel Role for DNA-PK in Metabolism by Regulating Glycolysis in Castration Resistant Prostate Cancer.
    Clin Cancer Res. 2022 Jan 25. pii: 1078-0432.CCR-21-1846.
    PubMed     Abstract available

    December 2021
  27. ZHAO JL, Fizazi K, Saad F, Chi KN, et al
    The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial.
    Clin Cancer Res. 2021 Dec 29. pii: 1078-0432.CCR-21-1090.
    PubMed     Abstract available

  28. BERCHUCK JE, Baca SC, McClure HM, Korthauer K, et al
    Detecting neuroendocrine prostate cancer through tissue-informed cell-free DNA methylation analysis.
    Clin Cancer Res. 2021 Dec 14. pii: 1078-0432.CCR-21-3762.
    PubMed     Abstract available

    November 2021
  29. PENG S, Hu P, Xiao YT, Lu W, et al
    Single-cell analysis reveals EP4 as a target for restoring T cell infiltration and sensitizing prostate cancer to immunotherapy.
    Clin Cancer Res. 2021 Nov 5. pii: 1078-0432.CCR-21-0299.
    PubMed     Abstract available

  30. AL-UBAIDI FLT, Schultz N, Loseva O, Egevad L, et al
    Editor's Note: Castration Therapy Results in Decreased Ku70 Levels in Prostate Cancer.
    Clin Cancer Res. 2021;27:6066.

    October 2021
  31. DORFF TB, Narayan V, Forman SJ, Zang PD, et al
    Novel Redirected T Cell Immunotherapies for Advanced Prostate Cancer.
    Clin Cancer Res. 2021 Oct 21. pii: 1078-0432.CCR-21-1483.
    PubMed     Abstract available

  32. STOPSACK KH, Nandakumar S, Arora K, Nguyen B, et al
    Differences in prostate cancer genomes by self-reported race: Contributions of genetic ancestry, modifiable cancer risk factors, and clinical factors.
    Clin Cancer Res. 2021 Oct 19. pii: 1078-0432.CCR-21-2577.
    PubMed     Abstract available

  33. LOEHR A, Patnaik A, Campbell D, Shapiro J, et al
    Response to rucaparib in BRCA-mutant metastatic castration-resistant prostate cancer identified by genomic testing in the TRITON2 study.
    Clin Cancer Res. 2021 Oct 1. pii: 1078-0432.CCR-21-2199.
    PubMed     Abstract available

    September 2021
  34. ZHANG H, Orme JJ, Abraha F, Stish BJ, et al
    Phase II evaluation of Stereotactic Ablative Radiotherapy (SABR) and immunity in (11)C-Choline-PET/CT-identified oligometastatic castration-resistant prostate cancer.
    Clin Cancer Res. 2021 Sep 30. pii: 1078-0432.CCR-21-2510.
    PubMed     Abstract available

  35. MIZUNO K, Sumiyoshi T, Okegawa T, Terada N, et al
    Clinical impact of detecting low-frequency variants in cell-free DNA on treatment of castration-resistant prostate cancer.
    Clin Cancer Res. 2021 Sep 15. pii: 1078-0432.CCR-21-2328.
    PubMed     Abstract available

  36. JEONG IG, Lim B, Yun SC, Lim JH, et al
    Adjuvant Low-dose Statin Use after Radical Prostatectomy: The PRO-STAT Randomized Clinical Trial.
    Clin Cancer Res. 2021;27:5004-5011.
    PubMed     Abstract available

    August 2021
  37. MOSTAGHEL EA, Marck BT, Kolokythas O, Chew F, et al
    Circulating and intra-tumoral adrenal androgens correlate with response to abiraterone in men with castration resistant prostate cancer.
    Clin Cancer Res. 2021 Aug 18. pii: 1078-0432.CCR-21-1819.
    PubMed     Abstract available

    July 2021
  38. MURTOLA TJ, Siltari A
    Statins for prostate cancer: when and how much?
    Clin Cancer Res. 2021 Jul 19. pii: 1078-0432.CCR-21-1891.
    PubMed     Abstract available

  39. SARKER D, Dawson NA, Aparicio AM, Dorff TB, et al
    A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kbeta inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2021 Jul 19. pii: 1078-0432.CCR-21-1115.
    PubMed     Abstract available

  40. BROWN LC, Halabi S, Schonhoft JD, Yang Q, et al
    Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide.
    Clin Cancer Res. 2021;27:4077-4088.
    PubMed     Abstract available

  41. DE BONO JS, Fleming MT, Wang JS, Cathomas R, et al
    Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody-Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide.
    Clin Cancer Res. 2021;27:3602-3609.
    PubMed     Abstract available

    June 2021
  42. TURNER PG, Jain S, Cole A, Grey A, et al
    Toxicity and efficacy of concurrent androgen deprivation therapy, pelvic radiotherapy, and radium-223 in patients with de-novo metastatic hormone sensitive prostate cancer.
    Clin Cancer Res. 2021 Jun 29. pii: 1078-0432.CCR-21-0685.
    PubMed     Abstract available

  43. CALAGUA C, Ficial M, Jansen CS, Hirz T, et al
    A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes.
    Clin Cancer Res. 2021 Jun 24. pii: 1078-0432.CCR-21-0121.
    PubMed     Abstract available

  44. TANG Z, Pilie PG, Geng C, Manyam GC, et al
    ATR inhibitor-induced CDK1-SPOP axis destabilizes PD-L1 and enhances cytotoxicity in prostate cancer.
    Clin Cancer Res. 2021 Jun 24. pii: 1078-0432.CCR-21-1010.
    PubMed     Abstract available

  45. KIM DH, Sun D, Storck WK, Welker Leng KR, et al
    BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program.
    Clin Cancer Res. 2021 Jun 18. pii: 1078-0432.CCR-20-4968.
    PubMed     Abstract available

  46. SMITH MR, Thomas S, Gormley M, Chowdhury S, et al
    Blood Biomarker Landscape in Patients with High-Risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease.
    Clin Cancer Res. 2021 Jun 10. pii: 1078-0432.CCR-21-0358.
    PubMed     Abstract available

  47. FONG L, Morris MJ, Sartor O, Higano CS, et al
    A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2021 Jun 9. pii: 1078-0432.CCR-21-0063.
    PubMed     Abstract available

  48. ANNALA M, Taavitsainen S, Khalaf DJ, Vandekerkhove G, et al
    Evolution of castration-resistant prostate cancer in ctDNA during sequential androgen receptor pathway inhibition.
    Clin Cancer Res. 2021 Jun 3. pii: 1078-0432.CCR-21-1625.
    PubMed     Abstract available

  49. HAWKEY NM, Armstrong AJ
    Liquid Biopsy: It's the Bloody Truth!
    Clin Cancer Res. 2021;27:2961-2963.
    PubMed     Abstract available

  50. HEGDE A, Jayaprakash P, Couillault CA, Piha-Paul S, et al
    A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies.
    Clin Cancer Res. 2021;27:3050-3060.
    PubMed     Abstract available

    May 2021
  51. HAMMER S, Schlicker A, Zitzmann-Kolbe S, Baumgart S, et al
    Darolutamide potentiates the antitumor efficacy of a PSMA-targeted thorium-227 conjugate (PSMA-TTC) by a dual mode-of-action in prostate cancer models.
    Clin Cancer Res. 2021 May 25. pii: 1078-0432.CCR-21-0342.
    PubMed     Abstract available

  52. MUNN LL, Stylianopoulos T, Jain NK, Hardin CC, et al
    Vascular Normalization to Improve Treatment of COVID-19: Lessons from Treatment of Cancer.
    Clin Cancer Res. 2021;27:2706-2711.
    PubMed     Abstract available

  53. KAWAMOTO K, Okino ST, Place RF, Urakami S, et al
    Editor's Note: Epigenetic Modifications of RASSF1A Gene through Chromatin Remodeling in Prostate Cancer.
    Clin Cancer Res. 2021;27:2665.

    April 2021
  54. TRUE LD, Chen DL
    How accurately does PSMA inhibitor 18F-DCFPyL-PET-CT image prostate cancer?
    Clin Cancer Res. 2021 Apr 23. pii: 1078-0432.CCR-21-0749.
    PubMed     Abstract available

  55. PRIVE BM, Peters SMB, Muselaers CHJ, van Oort IM, et al
    Lutetium-177-PSMA-617 in low-volume hormone sensitive metastatic prostate cancer, a prospective pilot study.
    Clin Cancer Res. 2021 Apr 21. pii: 1078-0432.CCR-20-4298.
    PubMed     Abstract available

  56. MCKAY RR, Kwak L, Crowdis J, Sperger JM, et al
    Phase 2 multicenter study of enzalutamide in metastatic castration resistant prostate cancer to identify mechanisms driving resistance.
    Clin Cancer Res. 2021 Apr 13. pii: 1078-0432.CCR-20-4616.
    PubMed     Abstract available

    March 2021
  57. WARNER E, Herberts C, Fu S, Yip S, et al
    BRCA2, ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression.
    Clin Cancer Res. 2021;27:1650-1662.
    PubMed     Abstract available

  58. CHAKRABORTY G, Patail NK, Hirani R, Nandakumar S, et al
    Attenuation of SRC Kinase Activity Augments PARP Inhibitor-mediated Synthetic Lethality in BRCA2-altered Prostate Tumors.
    Clin Cancer Res. 2021;27:1792-1806.
    PubMed     Abstract available

  59. LIN L, Kane N, Kobayashi N, Kono EA, et al
    High-dose per Fraction Radiotherapy Induces Both Antitumor Immunity and Immunosuppressive Responses in Prostate Tumors.
    Clin Cancer Res. 2021;27:1505-1515.
    PubMed     Abstract available

    January 2021
  60. RESCIGNO P, Gurel B, Pereira R, Crespo M, et al
    Characterizing CDK12-Mutated Prostate Cancers.
    Clin Cancer Res. 2021;27:566-574.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.